Compare Nuvalent Inc (NUVL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while State Street SPDR S&P Biotech ETF trades at $154.49. The key difference: Nuvalent Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| NUVL | XBI | |
|---|---|---|
Market Cap | $9.81B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $123.96 | $164.28 |
52-Week Low | $72.16 | $85.16 |
Enterprise Value | $8.52B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
